<DOC>
	<DOCNO>NCT00476073</DOCNO>
	<brief_summary>Open , parallel group design . The study screen phase 12 week treatment phase . Subjects randomise treatment 1:1 ration .</brief_summary>
	<brief_title>Efficacy Safety Flutiform® pMDI Adult Patients With Mild Moderate-severe Reversible Asthma</brief_title>
	<detailed_description>This study involve 12 week treatment phase . During treatment phase subject receive FLUTIFORM® Sertetide® . Efficacy assess lung function test asthma symptom , sleep disturbance . Safety assess adverse event , vital sign , lab test ECGs .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Male female patient least 18 year old ( female less one year postmenopausal must negative serum urine pregnancy test record within 72 hour prior first dose study medication , nonlactating , willing use adequate highly effective method contraception throughout study . A highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly sterilization , implant , injectables , combine oral contraceptive , IUDs ( Intrauterine Device , hormonal ) , sexual abstinence vasectomise partner ) . Known history mild moderatesevere reversible asthma &gt; 6 month prior screen visit . Demonstrate FEV1 &gt; 40 % &lt; 80 % predict normal value ( EGKS normal value , 1983 ) screen phase follow appropriate withhold asthma medication ( applicable ) . No beta agonist use day screen . No use combination asthma therapy day screen . Inhaled corticosteroid allow day screen . Documented reversibility &gt; 15 % FEV1 screening phase . Demonstrate satisfactory technique use pressurize MDI . Willing able enter information electronic diary attend study visit . Willing able substitute study medication pre study prescribe asthma medication duration study . Written inform consent obtain . Lifethreatening asthma within past year . This category include patient history nearfatal asthma , hospitalization emergency visit asthma prior intubation asthma . History systemic ( injectable ) corticosteroid medication within 1 month Screening Visit . History omalizumab use within past 6 month . History leukotriene receptor antagonist use , e.g . montelukast , within past week . Current evidence history clinically significant disease abnormality include uncontrolled coronary artery disease , congestive heart failure , myocardial infarction , cardiac dysrhythmia . 'Clinically significant ' defined disease , opinion Investigator , would put patient risk study participation , would affect outcome study . An upper low respiratory infection within 4 week prior Screening Visit . Significant , nonreversible , active pulmonary disease ( e.g. , chronic obstructive pulmonary disease ( COPD ) , cystic fibrosis , bronchiectasis , tuberculosis ) . Known Human Immunodeficiency Virus ( HIV ) positive status . A smoke history equivalent `` 10 pack year '' ( i.e. , least 1 pack 20 cigarette /day 10 year 10 packs/day 1 year , etc ) Current smoke history within 12 month prior Screening Visit . Current evidence history alcohol and/or substance abuse within 12 month prior Screening Visit . Patients take betablocking agent , tricyclic antidepressant , monoamine oxidase inhibitor , astemizole ( Hismanal ) , quinidine type antiarrhythmic , potent CYP 3A4 inhibitor ketoconazole within past week . Current use medication effect bronchospasm and/or pulmonary function . Current evidence history hypersensitivity idiosyncratic reaction test medication component . Receipt investigational drug within 30 day Screening Visit ( 12 week oral injectable steroid ) . Current participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>